跳至主要内容
临床试验/NCT06550960
NCT06550960尚未招募不适用

Evaluation of a Soft Tissue Biopsy System for Trans-rectal and Trans-perineal Biopsy of the Prostate Using Standard of Care and Artificial Intelligence (AI) Analysis

Uro-1 Medical0 个研究点目标入组 30 人开始时间: 2024年8月5日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
30
主要终点
Procedure success

研究概览

简要总结

This is a post-market study of a cleared biopsy system. The quality of tissue cores varies with standard of care biopsy needles. The SureCore Plus biopsy system is being evaluated as to quality and volume of tissue from prostate biopsy as compared to standard of care biopsy needles.

详细描述

Biopsy sampling of the prostate using TRUS or TPPB guidance is the current SoC approach for diagnosis of prostate cancer (CaP). Over the past decades the number of samples required and considered adequate has risen from 6 to 12-18 and sometimes as many as 30. Many practices routinely sample up to 20 cores of tissue. The SureCore Plus biopsy system is being to sample, obtain and retrieve prostate biopsy specimens in men undergoing scheduled diagnostic prostate biopsy and compare it with an standard of care (SoC) biopsy instrument and SoC method of specimen retrieval.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Patient has BPH requiring a prostate biopsy
  • Able and willing to provide consent

排除标准

  • Active infection
  • Subject participating in an other device study of the prostate

结局指标

主要结局

Procedure success

时间窗: During the procedure

\> 3 mm/cc of tissue collected in each biopsy

Quality of biopsy tissue

时间窗: During the procedure

Ranking by pathologist on scale of 0=unable to read to 5=all tissue complete for reading. The higher scores mean a better outcome.

次要结局

  • Performance of the study device(During the procedure)

研究者

发起方
Uro-1 Medical
申办方类型
Industry
责任方
Sponsor

相似试验

Evaluation of SureCore Plus Biopsy System | 临床试验